Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
salesforce.com, inc. (NYSE: CRM) stock was trading higher by around 5 percent early Wednesday morning in reaction to a non-GAAP first-quarter earnings beat along with a strong second quarter and full-year 2019 sales guidance.
Aslan Pharmaceuticals ADR (NASDAQ: ASLN) was trading higher by more than 5 percent on top of Tuesday's 14 percent gain. The clinical-stage biopharmaceutical company targeting cancers received bullish coverage from Street analysts, including H.C. Wainwright who initiated coverage of the stock with a Buy rating and $12 price target.
CorMedix Inc. (NYSE: CRMD) was trading higher by around 30 percent in reaction to a Phase 3 update. The biopharmaceutical company that focuses on treating infectious and inflammatory diseases said it reviewed and source-verified more than 75 percent of data for the interim analysis of its Phase 3 LOCK-IT 100 study for Neutrolin. Management expects to fully complete this work by the end of June.
Movado Group, Inc (NYSE: MOV) was trading higher by more than 10 percent in reaction to a first-quarter earnings bet and an upward revision of its sales and EPS outlook for fiscal 2019.
Michael Kors Holdings Ltd (NYSE: KORS) was trading lower by around 4 percent despite reporting a fiscal fourth-quarter beat and upbeat first-quarter guidance.
20 Stocks Moving In Wednesday's Pre-Market Session
Benzinga's Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data
See more from Benzinga
- PermRock's Stock A 'Straightforward Opportunity,' Stifel Says
- HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
- Is 0 Oil Imminent? This Pro Says Geopolitical Events Could Make It Happen
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.